Paul Ruff to Melanoma
This is a "connection" page, showing publications Paul Ruff has written about Melanoma.
Connection Strength
0,239
-
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS One. 2024; 19(11):e0309778.
Score: 0,239
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.